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P R E V I E W S
Deregulation of cell cycle control mecha-
nisms is an obligatory step in tumorigen-
esis. Myriad individual genetic events
lead to circumvention of checkpoints that
restrain the activity of cyclin/cyclin-
dependent kinase (cdk) complexes that
are responsible for managing cell cycle
transitions. Indeed, it is now widely
accepted that alteration of some compo-
nent of the retinoblastoma protein (pRb)
pathway, the core of which is depicted in
Figure 1, occurs in virtually all human
tumors. In some tumor cells, the RB gene
is a direct target of inactivating mutations,
but most often pRb is inactivated conse-
quent to inappropriate activation of the
cyclin D/cdk4(6) complex.This in turn can
be achieved through overexpression or
mutation of one of the subunits, or
through loss of the negative regulator
p16INK4a (Sherr and McCormick, 2002).
One of the most significant conse-
quences of pRb inactivation is activation
of cyclin E/cdk2 subunits, often as a
result of increased cyclin E expression.
Cyclin E/cdk2 complexes can themselves
participate in maintained inactivation of
pRb in tumor cells that express this pro-
tein, but also appear to have several
other critical roles in cell cycle progres-
sion (Bartek and Lukas, 2001). As shown
in Figure 1, cyclin E/cdk2 complexes are
thought to play critical roles in centro-
some duplication (Hinchcliffe and Sluder,
2002), replication origin firing (Krude et
al., 1997; Takisawa et al., 2000), and his-
tone protein expression (Ma et al. 2000;
Zhao et al., 2000). Consistent with such
crucial roles for cyclin E/cdk2 down-
stream of pRb, many tumor cells are
exquisitely sensitive to inactivation of
cyclin E/cdk2 whether or not they express
pRb. This conclusion has been drawn
from a multitude of experiments demon-
strating antiproliferative effects of overex-
pression of p27KIP1, a protein inhibitor of
cdk2, or of dominant-negative cdk2 sub-
units. Further, injection of antibodies
against cdk2 activators cyclin E and
cyclin A blocks proliferation, as does
treatment of many different cells with
cdk2 inhibitors (Tetsu and McCormick,
2003; Knockaert et al., 2002).
The view that pRb pathway inactiva-
tion has cyclin E/cdk2 activation as its
ultimate proliferative consequence is
supported by observations of mice engi-
neered to express cyclin E in place of
cyclin D1. Animals lacking cyclin D1 have
profound proliferative defects in a subset
of tissues, and fail to activate cdk2 in
those tissues.These phenotypes are sig-
nificantly suppressed in a knockin animal
that expresses cyclin E from the cyclin
D1 locus (Geng et al., 1999), suggesting
that loss of cyclin D-mediated inactiva-
tion of pRb is inconsequential if cyclin E
synthesis is no longer dependent on pRb
inactivation. Indeed, excess cyclin
E/cdk2 subunits can also overcome
ectopic expression of a nonphosphory-
latable, and thus constitutively active,
pRb (Bartek and Lukas, 2001). This
tumorigenic role of cyclin E/cdk2 may be
most clearly manifest in human breast
cancer cells, where reduced p27KIP1
expression or cyclin E overexpression
correlates well with aggressiveness of
the tumor (Catzavelos et al., 1997; Porter
et al., 1997; Keyomarsi et al., 2002). All
together, these studies suggest that
cyclin E/cdk2 regulation is targeted
directly and indirectly by multiple, collab-
orative mutational events in a wide vari-
ety of tumor cells and thus chemical
inhibition of cdk2 might provide an insur-
mountable obstacle to continued tumor
cell proliferation.
This view of cell cycle control in
cancer is now challenged by work from
Tetsu and McCormick reported in the
March issue of Cancer Cell. Using pri-
marily cell lines derived from colon can-
cers, Tetsu and McCormick have shown
that direct chemical inhibition of cdk4(6)
or indirect reduction of D cyclins and
cdk4 by MEK inhibitors blocks prolifera-
tion, but multiple modes of cdk2 inhibi-
tion are without effect. For example,
colon cancer cell lines proliferate with-
out regard to p27KIP1 or dncdk2 overex-
pression, but these same reagents do
cause arrest in other cell lines previous-
ly shown to respond to cdk2 inhibition.
Thus, colon cancer cells in general
appear to evade the effects of cdk2 inhi-
bition seen in other cancer cell types.
The authors suggest that one reason for
this is the ability of deregulated cdk4 to
fully inactivate pRb as a consequence
of eroded phosphorylation site specifici-
ty in tumor cells. Consistent with this,
Tetsu and McCormick show that one
form of dncdk4 can block proliferation of
Cdk2 dethroned as master of S phase entry
The prevailing view of cdk2 as a critical regulator of cell cycle progression and optimal therapeutic target in cancer cells is
now challenged by the observation that tumor cells deficient in cdk2 protein and kinase activity are not impaired in
proliferation.
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colon cancer cells that are immune to
cdk2 inhibition.
Extending this work to obtain greater
precision in assessing the role of cdk2 in
proliferation of cancer cells, Tetsu and
McCormick specifically reduced cdk2
expression using antisense oligonu-
cleotides or siRNA techniques. As
expected from results with p27KIP1 and
dncdk2 expression, this was without
effect in colon cancer cells. Remarkably,
however, several other tumor cell lines
tested also showed no effect of severe
cdk2 reduction, including those known to
be sensitive to p27KIP1 and dncdk2. This
quite surprising result suggests that the
cdk2 enzyme, long thought to be key to
the G1-to-S phase transition in both nor-
mal and tumor cells, may not be solely
responsible, nor indeed at all critical, for
this event in human tumor cells. From
this, the authors conclude that efforts to
specifically target cdk2 with small mole-
cule inhibitors as potential cancer thera-
peutics may be misguided.
Like any good, paradigm-shifting
work, the paper by Tetsu and McCormick
raises many crucial questions left for fur-
ther exploration. Two of these center on
the roles of p27KIP1 and cyclin E (and per-
haps cyclin A) as suppressor and activa-
tor of cell proliferation, respectively. First,
as discussed above, it is clear that unlike
the colon cancer cells studied here,
many tumor cells are indeed arrested by
p27KIP1 and dncdk2. If cdk2 activity is not
the specific target of this action, how
might these inhibitors work? One expla-
nation offered by the authors is inhibition
of cdk4, which may occur on the one
hand through an inhibitory action of high
levels of p27KIP1, or on the other hand
through a titration of p27KIP1 (or p21CIP1)
by dncdk2, leading to a reduction in the
assembly of functional cyclin D/cdk4(6)
complexes. This, however, is unlikely to
explain the effect of p27KIP1 and dncdk2
on pRb-minus cells that typically lack
detectable cdk4(6) activity as a conse-
quence of elevated p16INK4a expression.
An attractive alternative possibility is
that a distinct kinase subunit other than
cdk2 may be able to partner with cyclin E
in a p27KIP1-sensitive manner in such
cells. A candidate for such a kinase in
human cells is cdk3, which has been
shown to be activated by cyclin E2
(Zariwala et al., 1998). However, if this is
the case, the tumor cells tested in the
Tetsu and McCormick study must be
able to proliferate with very low levels of
cyclin E-associated kinase activity, since
this was undetectable in cells treated
with cdk2 antisense oligonucleotides. A
second possibility that is not mutually
exclusive with this is that a non-cdk
kinase might be able to drive all of the
events ascribed to cdk2 in Figure 1, at
least in tumor cells. A candidate here that
has recently generated much interest is
aurora kinase. Aurora kinase is overex-
pressed in some cancers and has been
linked to centrosome duplication and cel-
lular transformation (Duterte et al.,
2002). Perhaps unscheduled activation
of aurora kinase greatly limits the
requirement for cdk2 in tumor cells—just
as ectopic expression of cyclin E pre-
cludes the need for cyclin D1 in certain
mouse tissues as described above.
Indeed, given that cdk2 cannot be said
for certain to be completely absent after
siRNA or antisense treatment, minute
amounts of activity may collaborate with
kinases such as aurora to drive cancer
cell cycles. Regardless, proliferation of
cancer cells with such a paltry amount of
cdk2 challenges the chemist targeting
cdk2 in tumors.
Finally, the present study ups the
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Figure 1. The RB pathway and the role of cdk2 in cell cycle progression
Inactivation of the transcriptional repressor function of the retinoblastoma protein is required for
the G1-to-S phase transition. In normal cells, this is achieved through mitogen-induced activa-
tion of cyclin D/cdk4(6) complexes, the assembly of which is facilitated by p21CIP1 and p27KIP1,
leading to phosphorylation and inactivation of pRb. This event correlates well with passage
through the restriction point (R), after which cells remain committed to DNA replication even in
the absence of mitogens (Pardee, 1989). Upon phosphorylation by D/cdk4(6), pRb loses its abil-
ity to inhibit E2F-dependent transcription and cyclin E levels increase. Subsequent activation of
cdk2 leads to further phosphorylation of pRb and has recently been proposed to be critical for
several other aspects of S phase entry. Cyclin E/cdk2 complexes can phosphorylate the tran-
scription factor p220NPAT, leading to activation of histone gene promoters. Phosphorylation of
nucleophosmin is one of several events in centrosome duplication that may be directly or indi-
rectly controlled by cyclin E/cdk2, and cdk2 activity appears to contribute to cdc45 loading
onto licensed origins of DNA replication, a prerequisite to origin firing. When conditions inappro-
priate for proliferation are sensed, these events can be blocked by p16INK4a-mediated inhibition
of cyclin D/cdk4(6) assembly and activation or by de novo synthesis of elevated levels of p21CIP1
and p27KIP1 that potently inhibit cdk2. Loss of pRb or p16INK4a or overexpression of cyclin D/cdk4(6)
complexes is seen in most cancers and may synergize with enhanced degradation of p27KIP1 or
increased cyclin E level to promote unchecked entry into S phase.
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ante for those betting types who strive
to predict the phenotype of mice lacking
the E type cyclins or cdk2, or of normal
human cells treated to lack these mole-
cules. Based on current dogma, many
would place their money on an absolute
requirement for cdk2 or E cyclins in nor-
mal cell cycles. Given the work present-
ed by Tetsu and McCormick, the payoff
may go to those betting on less pro-
found phenotypes, and such experi-
ments will likely force the preparation of
a new set of model slides for all those
with interest in cdk2’s role in mam-
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In the United States and much of the
Western world, breast cancer rivals lung
cancer as the most frequent cause of
cancer-related death in women, with
upwards of 12 percent of women diag-
nosed with breast cancer during their life-
times. While breast cancer mortality
appears to have shown some encourag-
ing decreases in the recent past, present-
ly, about 25% of women diagnosed with
breast cancer will die of the disease
(Baselga and Norton, 2002). Hormonal
factors play a key role in normal breast
development and in growth and progres-
sion of breast cancer.
Perhaps chief among the hormonal
factors involved in breast cancer is the
ovarian steroid hormone estrogen. The
biological actions of estrogen are
dependent on the cellular function of a
high-affinity estrogen receptor (ER)
(McDonnell and Norris, 2002). Two estro-
gen receptors—ERα and ERβ—have
been identified, but most estrogenic
responses appear to require ERα. Upon
binding estrogen or other ligands, ER is
released from its inhibition by a large heat
shock protein complex. Following dimer-
ization, ER activates transcription of spe-
cific cellular genes via direct and indirect
interactions with their regulatory regions.
In breast cancer cells expressing ER,
estrogen has potent effects on cell prolif-
eration, differentiation, and survival, per-
haps in part via estrogen’s ability to affect
the cellular response to various growth
factors and other cues from surrounding
extracellular matrix and stromal cells.
While ER expression in breast cancer is
generally associated with a better clinical
outcome, the clinical utility of ER as a
prognostic marker is modest. Rather, the
principal value of defining the ER status
(and the progesterone receptor status) of
a breast cancer is for prediction of the
patient’s likely response to systemic ther-
apy, particularly adjuvant therapy with
tamoxifen, a selective estrogen receptor
modifier and antiestrogenic agent in the
breast (Baselga and Norton, 2002).
Besides hormonal and other envi-
ronmental factors, germline and somatic
mutations and gene expression changes
play key roles in breast cancer initiation
and progression. There is great interest
in defining how the various mutations
and gene expression changes contribute
to breast cancer development and its
aggressive behavior, especially because
recent studies have indicated that partic-
ular gene expression signatures in
breast cancer are associated with good
prognosis and other signatures are
associated with poor prognosis (van de
Vijver et al., 2002). A major challenge for
workers pursuing gene expression
Connecting estrogen receptor function, transcriptional repression,
and E-cadherin expression in breast cancer
A recent paper in Cell (Fujita et al., 2003) demonstrates that MTA3, a novel component of the Mi-2/NuRD transcriptional repres-
sion complex, is an estrogen receptor-regulated inhibitor of the Snail zinc finger transcription factor in breast cancer. Given
the important role of Snail in repressing E-cadherin transcription and the function of E-cadherin as a tumor suppressor pro-
tein and regulator of epithelial architecture, the findings offer potentially significant new insights into cancer pathogenesis.
